JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

60.87 3.66

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

58.35

Макс.

61.73

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

-13.29% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.2B

3.8B

Предыдущая цена открытия

57.21

Предыдущая цена закрытия

60.87

Новостные настроения

By Acuity

50%

50%

178 / 348 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 апр. 2026 г., 00:00 UTC

Отчет

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 апр. 2026 г., 23:47 UTC

Обсуждения рынка

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 апр. 2026 г., 23:43 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 апр. 2026 г., 23:43 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 апр. 2026 г., 23:43 UTC

Обсуждения рынка

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 апр. 2026 г., 23:13 UTC

Приобретения, слияния, поглощения

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 апр. 2026 г., 22:33 UTC

Отчет

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 апр. 2026 г., 22:17 UTC

Отчет

PLS Executed Offtake Agreement With Ronbay

23 апр. 2026 г., 22:17 UTC

Отчет

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 апр. 2026 г., 22:16 UTC

Отчет

PLS Commences Commissioning of Midstream Demonstration Plant

23 апр. 2026 г., 22:15 UTC

Отчет

PLS Group Reaffirms FY26 Guidance for All Metrics

23 апр. 2026 г., 22:14 UTC

Отчет

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 апр. 2026 г., 22:14 UTC

Отчет

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 апр. 2026 г., 22:13 UTC

Отчет

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 апр. 2026 г., 22:12 UTC

Отчет

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 апр. 2026 г., 22:12 UTC

Отчет

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 апр. 2026 г., 22:11 UTC

Отчет

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 апр. 2026 г., 22:10 UTC

Отчет

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 апр. 2026 г., 22:09 UTC

Отчет

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 апр. 2026 г., 22:08 UTC

Отчет

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 апр. 2026 г., 22:04 UTC

Отчет

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 апр. 2026 г., 21:56 UTC

Обсуждения рынка
Отчет

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 апр. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 апр. 2026 г., 21:27 UTC

Отчет

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 апр. 2026 г., 21:25 UTC

Отчет

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 апр. 2026 г., 21:24 UTC

Отчет

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 апр. 2026 г., 21:24 UTC

Отчет

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 апр. 2026 г., 21:21 UTC

Отчет

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 апр. 2026 г., 21:21 UTC

Отчет

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

-13.29% падение

Прогноз на 12 месяцев

Средняя 54.8 USD  -13.29%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

178 / 348Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat